Selective Targeting of Highly Cytotoxic T Cells in Autoimmune Diseases
Abcuro is developing its lead product candidate ABC008 for autoimmune disorders and rare cancers, including inclusion body myositis (IBM), T Cell Large Granular Lymphocytic Leukemia (T-LGLL) and T and NK cell lymphomas. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting killer cell lectin-like receptor G1 (KLRG1), a marker selectively expressed on these highly cytotoxic T cells.
In IBM and T-LGLL, cytotoxic T cells are a major source of chronic tissue damage. For mature T and NK cell lymphomas, the KLRG1 expressing T cells or NK cells are malignant. In November 2021, we presented initial results from a Phase 1 open-label trial of ABC008 in IBM at American College of Rheumatology Convergence 2021 (view poster) and an updated dataset was presented at GCOM 2022 (view poster). In this trial, ABC008 demonstrated potent depletion of KLRG1+ T cells in patients with IBM.
Martin, Alex
Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

Alex Martin
Chief Executive Officer

Alex Martin
Chief Executive Officer
Wilkins, Jeffrey
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

H. Jeffrey Wilkins, MD
Chief Medical Officer

H. Jeffrey Wilkins, MD
Chief Medical Officer
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.
Tubridy, Karen
Karen Tubridy is the Chief Operating Officer of Abcuro. She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND,

Karen Tubridy, PharmD
Chief Operating Officer

Karen Tubridy, PharmD
Chief Operating Officer
Amador, Stephanie

Stephanie Amador
Senior Manager,
CMC Project Management

Stephanie Amador
Senior Manager,
CMC Project Management
Borbas, Dave

Dave Borbas
Research VP,
Head of Data Management

Dave Borbas
Research VP,
Head of Data Management
Brennan, Eileen

Eileen Brennan
Senior Manager, Regulatory Affairs

Eileen Brennan
Senior Manager, Regulatory Affairs
Byrne, Donna

Donna Byrne
Director, Clinical Operations

Donna Byrne
Director, Clinical Operations
Chaney, Terry

Terry Chaney
Associate Director,
GMP QA Operations

Terry Chaney
Associate Director,
GMP QA Operations
Chartienitz, Brett

Brett Chartienitz
IT Operations Manager

Brett Chartienitz
IT Operations Manager
Chen, Weilee

Weilee Chen
Senior Manager,
CMC Downstream Manufacturing

Weilee Chen
Senior Manager,
CMC Downstream Manufacturing
Cooper, Ken

Ken Cooper
Clinical Operations, Trial Management

Ken Cooper
Clinical Operations, Trial Management
Geary, Jeff

Jeff Geary
Director, Human Resources

Jeff Geary
Director, Human Resources
Greenberg, Steven A.
Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics,

Steven A. Greenberg, MD
Chief Scientific Advisor & Co-Founder

Steven A. Greenberg, MD
Chief Scientific Advisor & Co-Founder
Gress, Mike

Mike Gress
VP, Clinical Development,
Head of Clinical Trial Management

Mike Gress
VP, Clinical Development,
Head of Clinical Trial Management
Han Fang

Fang Han
Associate Director, FP&A

Fang Han
Associate Director, FP&A
Hoffer, LaDonna

LaDonna Hoffer
Project Manager

LaDonna Hoffer
Project Manager
Houts, Ian

Ian Houts
Senior Director, Supply Chain

Ian Houts
Senior Director, Supply Chain
Hwang, Ella

Ella Hwang
Vice President, Quality

Ella Hwang
Vice President, Quality
Jiang, Lusi

Lusi Jiang
Accounting Manager

Lusi Jiang
Accounting Manager
LeMessurier, Hugo

Hugo LeMessurier
Director, Abcuro Pty Ltd

Hugo LeMessurier
Director, Abcuro Pty Ltd
Lewis, Samantha

Samantha Lewis
Associate Director,
CMC Supply Chain and Logistics

Samantha Lewis
Associate Director,
CMC Supply Chain and Logistics
Luk, Jeffrey

Jeffrey Luk
Director, Head of Manufacturing

Jeffrey Luk
Director, Head of Manufacturing
Lurk, Kristin

Kristin Lurk
Senior Director
Program Management

Kristin Lurk
Senior Director
Program Management
Mansuri, Daniel

Daniel Mansuri
Head of Corporate Development

Daniel Mansuri
Head of Corporate Development
Marth, Andrew

Andrew Marth
Director, Quality Control

Andrew Marth
Director, Quality Control
Martin, Alex
Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

Alex Martin
Chief Executive Officer

Alex Martin
Chief Executive Officer
McClain, Michael

Michael McClain
Associate Director, Clinical Operations

Michael McClain
Associate Director, Clinical Operations
Motschwiller, Ricky

Richard Motschwiller
VP, Finance

Richard Motschwiller
VP, Finance
Nguyen, Charlie

Charlie Nguyen
Senior Manager, CMC Process Development

Charlie Nguyen
Senior Manager, CMC Process Development
Obi, Chidi

Chidi Obi
Director, Analytical Development

Chidi Obi
Director, Analytical Development
Orozco, Raquel

Raquel Orozco
Director, CMC
Process Development

Raquel Orozco
Director, CMC
Process Development
Patel, Zarna

Zarna Patel
Director, Quality Systems

Zarna Patel
Director, Quality Systems
Pepen, Johnny

Johnny Pepen
Staff Accountant

Johnny Pepen
Staff Accountant
Reyes, Armando

Armando Reyes
Director, Clinical Operations

Armando Reyes
Director, Clinical Operations
Searle, Stephen

Stephen A. Searle
Senior Program Manager

Stephen A. Searle
Senior Program Manager
Shen, Yuyi

Yuyi Shen, PhD
VP, Technical Operations

Yuyi Shen, PhD
VP, Technical Operations
Soler-Ferran, Dulce, PhD

Dulce Soler-Ferran, PhD
VP, Biology

Dulce Soler-Ferran, PhD
VP, Biology
Srinivasan, Usha

Usha Srinivasan
Vice President, Regulatory Affairs

Usha Srinivasan
Vice President, Regulatory Affairs
Sundaram, Sam

Sam Sundaram
Executive Assistant & Operations Manager

Sam Sundaram
Executive Assistant & Operations Manager
Tashi, Karma

Karma Tashi
Director, GMP Quality Drug Substance

Karma Tashi
Director, GMP Quality Drug Substance
Tubridy, Karen
Karen Tubridy is the Chief Operating Officer of Abcuro. She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND,

Karen Tubridy, PharmD
Chief Operating Officer

Karen Tubridy, PharmD
Chief Operating Officer
Weems Gary

Garry Weems
VP, Clinical Science

Garry Weems
VP, Clinical Science
Wilkins, Jeffrey
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

H. Jeffrey Wilkins, MD
Chief Medical Officer

H. Jeffrey Wilkins, MD
Chief Medical Officer
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.
Yates, Bill

Bill Yates
Vice President, Information Technology

Bill Yates
Vice President, Information Technology
Pruzanski, Mark
Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief Executive Officer of Versanis Bio where he spearheaded the development of novel therapies for obesity and other cardiometabolic diseases until the company’s acquisition in 2023 by Eli Lilly and

Mark Pruzanski, MD
Chairman of the Board

Mark Pruzanski, MD
Chairman of the Board
Martin, Alex
Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA

Alex Martin
Chief Executive Officer

Alex Martin
Chief Executive Officer
Boyce, Sarah
Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of global leadership experience in both pharmaceutical and biopharmaceutical companies. Sarah’s tenure at Avidity has been marked by transformative leadership, starting with the company’s successful Series C funding

Sarah Boyce
President and Chief Executive Officer
Avidity Biosciences

Sarah Boyce
President and Chief Executive Officer
Avidity Biosciences
Dybbs, Mike
Mike is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Mike was a partner at New Leaf Venture Partners. Before New Leaf Venture Partners Mike was a principal at the Boston Consulting Group, where he consulted for biotech and pharma clients. Mike currently serves on the

Mike Dybbs, PhD
Partner, Samsara BioCapital

Mike Dybbs, PhD
Partner, Samsara BioCapital
Fang, Ming
Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare space as an investor at Safeguard Scientifics, a consultant at McKinsey & Company and ZS Associates, and an operator at Gilead Sciences. He received a BA in Computer Science from

Ming Fang
Managing Director, Redmile Group

Ming Fang
Managing Director, Redmile Group
Hafler, Jason P. , PhD
Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow,

Jason P. Hafler, PhD
Managing Director, Sanofi Ventures

Jason P. Hafler, PhD
Managing Director, Sanofi Ventures
Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA Therapeutics, a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm. Jason’s active investments include Abcuro, Amathus Therapeutics, Escient Pharmaceuticals, Expansion Therapeutics, Glycomine, Q32 Bio, ReCode Therapeutics, Rome Therapeutics and Navitor Pharmaceuticals. Jason graduated with honors from Bowdoin College and holds a PhD from the University of Cambridge.
Park, Michele
Michele Park joined NEA in 2021 as an investor on the Healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at Clarus Ventures (now Blackstone Life Sciences). Previously, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray. Michele received her PhD in molecular biology from

Michele Park, PhD
Partner, New Enterprise Associates

Michele Park, PhD
Partner, New Enterprise Associates
Shah, Rajeev
Rajeev Shah has been a Managing Partner at RA Capital Management since 2004. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. He previously worked as a

Rajeev Shah
Managing Partner, RA Capital Management

Rajeev Shah
Managing Partner, RA Capital Management
Cashdan, Jonah
Jonah Cashdan joined Bain Capital Life Sciences in 2018. Prior to joining Bain Capital, he worked at J.P. Morgan in their healthcare investment banking group, evaluating and executing strategic alternatives including M&A and debt/equity financings for clients across the pharmaceutical, biotech and medtech sectors. Prior to joining J.P. Morgan, Jonah studied synaptic physiology and sensory system

Jonah Cashdan
Observer
Principal, Bain Capital Life Sciences

Jonah Cashdan
Observer
Principal, Bain Capital Life Sciences
Knowles, Julius (Jay)
Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics. Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President

Julius (Jay) Knowles
Observer
Partner, Mass General Brigham Ventures

Julius (Jay) Knowles
Observer
Partner, Mass General Brigham Ventures
Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by Juno Therapeutics. Prior to X-BODY, he was at Novartis in charge of the Platforms team for Strategic Alliances, responsible for global technology and drug discovery collaborations. Jay was also President of Novalar Pharmaceuticals, Vice President of Business Development at Novacea, and Director, R&D Planning at Vertex Pharmaceuticals. He represents Mass General Brigham Ventures on the boards of Apres Therapeutics, Keros Therapeutics, SwanBio Therapeutics, and Triplet Therapeutics. Jay earned his MBA in Finance from Wharton Business School, an MSc in Chemistry from UC Berkeley, and a BA with Distinction in Chemistry from Carleton College.